GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » AdaptHealth Corp (NAS:AHCO) » Definitions » ROE %

AdaptHealth (AdaptHealth) ROE % : -0.58% (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is AdaptHealth ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. AdaptHealth's annualized net income for the quarter that ended in Mar. 2024 was $-9 Mil. AdaptHealth's average Total Stockholders Equity over the quarter that ended in Mar. 2024 was $1,460 Mil. Therefore, AdaptHealth's annualized ROE % for the quarter that ended in Mar. 2024 was -0.58%.

The historical rank and industry rank for AdaptHealth's ROE % or its related term are showing as below:

AHCO' s ROE % Range Over the Past 10 Years
Min: -102.28   Med: -9.48   Max: 12.92
Current: -38.74

During the past 7 years, AdaptHealth's highest ROE % was 12.92%. The lowest was -102.28%. And the median was -9.48%.

AHCO's ROE % is ranked worse than
73.08% of 806 companies
in the Medical Devices & Instruments industry
Industry Median: -0.36 vs AHCO: -38.74

AdaptHealth ROE % Historical Data

The historical data trend for AdaptHealth's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AdaptHealth ROE % Chart

AdaptHealth Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
Get a 7-Day Free Trial -20.65 -102.28 12.92 3.29 -37.62

AdaptHealth Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.91 2.58 -92.82 -63.81 -0.58

Competitive Comparison of AdaptHealth's ROE %

For the Medical Devices subindustry, AdaptHealth's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AdaptHealth's ROE % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, AdaptHealth's ROE % distribution charts can be found below:

* The bar in red indicates where AdaptHealth's ROE % falls into.



AdaptHealth ROE % Calculation

AdaptHealth's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=-678.895/( (2151.158+1458.454)/ 2 )
=-678.895/1804.806
=-37.62 %

AdaptHealth's annualized ROE % for the quarter that ended in Mar. 2024 is calculated as

ROE %=Net Income (Q: Mar. 2024 )/( (Total Stockholders Equity (Q: Dec. 2023 )+Total Stockholders Equity (Q: Mar. 2024 ))/ count )
=-8.536/( (1458.454+1461.789)/ 2 )
=-8.536/1460.1215
=-0.58 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2024) net income data. ROE % is displayed in the 30-year financial page.


AdaptHealth  (NAS:AHCO) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Mar. 2024 )
=Net Income/Total Stockholders Equity
=-8.536/1460.1215
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-8.536 / 2376.396)*(2376.396 / 4506.1715)*(4506.1715 / 1460.1215)
=Net Margin %*Asset Turnover*Equity Multiplier
=-0.36 %*0.5274*3.0862
=ROA %*Equity Multiplier
=-0.19 %*3.0862
=-0.58 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Mar. 2024 )
=Net Income/Total Stockholders Equity
=-8.536/1460.1215
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-8.536 / 22.004) * (22.004 / 228.244) * (228.244 / 2376.396) * (2376.396 / 4506.1715) * (4506.1715 / 1460.1215)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= -0.3879 * 0.0964 * 9.6 % * 0.5274 * 3.0862
=-0.58 %

Note: The net income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


AdaptHealth ROE % Related Terms

Thank you for viewing the detailed overview of AdaptHealth's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


AdaptHealth (AdaptHealth) Business Description

Traded in Other Exchanges
N/A
Address
220 West Germantown Pike, Suite 250, Plymouth Meeting, PA, USA, 19462
AdaptHealth Corp is engaged in providing patient-centered, healthcare-at-home solutions including home medical equipment (HME), medical supplies, and related services. It focuses on providing; sleep therapy equipment, supplies, and related services (including CPAP and bi-PAP services) to individuals suffering from obstructive sleep apnea (OSA), medical devices and supplies to patients for the treatment of diabetes (including continuous glucose monitors (CGM and insulin pumps), home medical equipment to patients discharged from acute care and other facilities, oxygen and related chronic therapy services in the home, and other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy and nutritional supply needs.
Executives
Williams David Solomon Iii director 6272 CONDON AVE, LOS ANGELES CA 90056
Skyknight Aero Holdings, Llc director C/O SKYKNIGHT CAPITAL, L.P., ONE LETTERMAN DR., BLDG. C, SUITE 3-950, SAN FRANCISCO CA 94129
Albert A. Prast officer: Chief Technology Officer 3325 BARTLETT BLVD., ORLANDO FL 32811
Jason A Clemens officer: Chief Financial Officer 220 WEST GERMANTOWN PIKE, SUITE 250, C/O ADAPTHEALTH LLC, PLYMOUTH MEETING PA 19462
Christine E. Archbold officer: Chief Accounting Officer FRIARS HOUSE, 160 BLACKFRIARS ROAD, LONDON X0 SEL 8EZ
Everest Hill Group Inc. 10 percent owner TROPIC ISLE BUILDING, P O BOX 3331, ROAD TOWN TORTOLA D8 VG 1110
Daniel Bunting officer: COO - Branch Operations 12200 N.W. AMBASSADOR DRIVE, SUITE 326, KANSAS CITY MO 64163
Shaw Rietkerk officer: Chief Revenue Officer C/O ADAPTHEALTH LLC, 220 WEST GERMANTOWN PIKE, SUITE 250, PLYMOUTH MEETING PA 19462
Christopher J Joyce officer: General Counsel C/O ALLIANCE ENTERTAINMENT CORP, 110 EAST 59TH STREET 18TH FLOOR, NEW YORK NY 10022
Skyknight Aero Holdings Ii, Llc director C/O SKYKNIGHT CAPITAL, L.P., ONE LETTERMAN DR., BLDG. C, SUITE 3-950, SAN FRANCISCO CA 94129
Skyknight Capital, L.p. director C/O SKYKNIGHT CAPITAL, ONE LETTERMAN DR., BLDG. C, SUITE 3-950, SAN FRANCISCO CA 94129
Skyknight Capital Fund Ii, L.p. director ONE LETTERMAN DRIVE, BUILDING C, SUITE 3-950, SAN FRANCISCO CA 94129
Stephen P Griggs director, officer: Co-Chief Executive Officer 1360 PLACE VENDOME, WINTER PARK FL 32789
Gregory Belinfanti director 7500 RIALTO BLVD, BLDG TWO, STE 100, AUSTIN TX 78735
Frank Mullen officer: Chief Accounting Officer 4553 GLENCOE AVENUE, SUITE 300, LOS ANGELES CA 90292

AdaptHealth (AdaptHealth) Headlines

From GuruFocus